A Study of V940 Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer
The goal of this study is to evaluate V940 plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of completely resected (R0) Stage II, IIIA, IIIB (with nodal involvement [N2])